Fighting falsified and substandard medicines: acting on evidence in Indonesia and Afghanistan

Frequently asked question


In this session, we focus on the fight against falsified and substandard medicines in Indonesia and Afghanistan, presenting original studies on the size and nature of the problem and proposing solutions. How big is the problem? What are the root causes and what can be done to protect patients from poor-quality medicines? We will explore different methods for assessing the quality of medicines in both the public and private sector and present empirical examples of both random and risk-based sampling, patient perceptions, and an ongoing review of which medicines in the market are most at risk.

Our interactive session will center on what can be done to reduce the chance that falsified and substandard medicine penetrate the market and reach patients. We will focus on how research can be used to ensure the safety and efficacy of pharmaceutical products and the need for intergovernmental collaboration, between departments and sectors, regulatory bodies, healthcare providers, and other stakeholders who play a role in ensuring the quality of medicines. Ultimately, our goal is to contribute to the global effort to address the drug quality crisis and improve access to safe and effective medicines for all.


  • Elisabeth Kleipool, Advisor Health Systems Strengthening, PhD, KIT Royal Tropical Institute

  • Nima Yaghmaei, Epidemiologist, KIT Royal Tropical Institute

  • Sandra Alba, PhD, Senior Epidemiologist, KIT Royal Tropical Institute

  • Amalia Hasnida, Erasmus School for Health Policy and Management, Erasmus University Rotterdam

  • Dr. Maarten Kok, Erasmus School for Health Policy and Management, Erasmus University Rotterdam, Universitas Gadjah Mada